Definium Therapeutics CEO Robert Barrow Buys 375,000 Shares
Robert Barrow, CEO of Definium Therapeutics, purchased 375,000 shares on June 22.
Key Points
- Robert Barrow, CEO of Definium Therapeutics, bought 375,000 shares on June 22, 2026.
- Shares of Definium Therapeutics traded near $24.48 on Monday with a market cap of about $2.67 billion.
- Several analysts, including Canaccord Genuity and Piper Sandler, maintained a buy rating on Definium Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Robert Barrow, the CEO of Definium Therapeutics, Inc. (NasdaqGS: DFTX), purchased 375,000 shares of the company. This insider transaction did not have a disclosed transaction value or price per share.
Insider Buying and Selling at Definium Therapeutics, Inc.
In addition to Robert Barrow, other top executives at Definium Therapeutics also bought shares on June 22, 2026. Chief Medical Officer Daniel Karlin purchased 100,000 shares, Chief Legal Officer Mark Sullivan bought 62,500 shares, Chief Financial Officer Brandi Roberts acquired 62,500 shares, and Chief Commercial Officer Matthew Wiley added 62,500 shares to his holdings. These transactions were not executed under a pre-arranged 10b5-1 plan.
Other Institutional Activity in Definium Therapeutics
Several institutional investors have shown interest in Definium Therapeutics. BlackRock, Inc. opened a new position with 8,480,230 shares valued at approximately $160.3 million. Driehaus Capital Management LLC reduced its holdings by 625,313 shares, leaving it with 5,911,889 shares worth about $111.7 million, marking a 9.6% decrease. Avoro Capital Advisors LLC initiated a stake with 5,000,000 shares valued at $94.5 million. Janus Henderson Group PLC also opened a new position, holding 3,556,041 shares valued at $67.2 million. Deep Track Capital, LP joined with 3,000,000 shares worth $56.7 million.
Definium Therapeutics, Inc. Stock Down 10.5%
Shares of Definium Therapeutics traded near $24.48 on Monday. The company, with a market cap of approximately $2.67 billion, operates in the biotechnology sector. It has a forward P/E ratio of -15.48, indicating it is not currently profitable. The stock's 52-week range is between $6.35 and $26.25, with a 50-day moving average of $22.61 and a 200-day moving average of $16.28. The company has a current ratio of 4.69 and a quick ratio of 4.60, with a debt-to-equity ratio of 14.62.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 16, 2026, Canaccord Genuity maintained its buy rating on Definium Therapeutics with a price target of $38. Piper Sandler also maintained a buy rating with a target of $48, and Leerink Partners set a target of $30 with a buy rating. The consensus among 15 analysts is a strong buy, with a mean target price of $39.87.
About Definium Therapeutics
Definium Therapeutics, Inc. is a clinical biopharmaceutical company based in New York, NY. It focuses on developing novel treatments for brain health disorders. The company’s lead products include DT120, in phase 3 trials for generalized anxiety disorder and major depressive disorder, and DT402, in phase 2a trials for autism spectrum disorder. Definium Therapeutics was previously known as Mind Medicine (MindMed) Inc. and rebranded in January 2026.
Bottom Line
Robert Barrow's recent purchase of 375,000 shares highlights insider confidence in Definium Therapeutics. The stock has seen significant institutional interest, with new positions opened by major funds. Analysts are optimistic, maintaining buy ratings with various price targets. Investors will keep an eye on the company's next earnings report on July 30, 2026.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.